JANX Q4 2022 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+76.1% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$18M-642.0% margin

Net Income

-$16M-564.7% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+56.9%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$14M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$364M

Total Liabilities

$43M

Stockholders' Equity

$321M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+76.1%
Gross Profit	$3M	-$10M	+129.8%
Operating Income	-$18M	-$13M	-35.4%
Net Income	-$16M	-$13M	-19.7%